Ara Dikranian, MD
Rheumatology · San Diego, CANPI 1609962026
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,554,212 of the $2,206,553 with a category attached, or 70.4%. It is spread thinly across 58 manufacturers, the largest accounting for just 22.1%. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,760 payments — averaging $586.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$488K
- Mallinckrodt Hospital Products Inc.$337K
- Boehringer Ingelheim$260K
- Amgen$170K
- Lilly USA, LLC$154K
- Sanofi$153K
- plus $644K from 52 others
Across 122 payments — averaging $2954.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$96K
- UCB SA$73K
- Amgen$73K
- E.r. Squibb & Sons, L.L.C.$42K
- Astrazeneca UK Limited$26K
- Janssen Research & Development, LLC$16K
- plus $34K from 3 others
What the payments were for
- Consulting fees$369,55717%
- Speaking & faculty fees$1,554,21270%
- Travel & lodging$191,7129%
- Food & beverage$90,5424%
- Education$4900%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,206,553 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 15 | $1,245,631 |
| Humira(Cf) PenAdalimumab | 54 | $469,778 |
| Enbrel SureclickEtanercept | 58 | $433,725 |
| Xeljanz XrTofacitinib Citrate | 53 | $409,693 |
| RinvoqUpadacitinib | 54 | $354,456 |
| OfevNintedanib Esylate | 23 | $288,350 |
| Taltz AutoinjectorIxekizumab | 37 | $247,574 |
| Orencia ClickjectAbatacept | 44 | $244,835 |
| RayosPrednisone | 31 | $171,015 |
| OrenciaAbatacept | 13 | $72,913 |
| KevzaraSarilumab | 14 | $60,442 |
| Actemra ActpenTocilizumab | 12 | $52,720 |
| ProliaDenosumab | 26 | $45,848 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $35,118 |
| OtrexupMethotrexate/Pf | 17 | $18,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $337,226 | $1,245,63115 claims |
| AbbVieRinvoq | $487,967 | $354,45654 claims |
| Boehringer IngelheimOfev | $259,722 | $288,35023 claims |
| AmgenRayos, Prolia | $169,800 | $216,86357 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $5,564 | $72,91313 claims |
| SanofiKevzara | $153,390 | $60,44214 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $185 | $2,86831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 rheumatology providers in California.
Other rheumatology in San Diego
- Arthur MabaquiaoSan Diego$209K
- Kenneth KalunianSan Diego$194K
- Sudhakar TumuluriSan Francisco$2.8M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.